TICKERNERD
Menu
WGSWGSHealthcare · Diagnostics & Research

WGS Stock Forecast: GeneDx Holdings Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$78
−1.35% on the day

The 9 Wall Street analysts covering GeneDx Holdings Corp. hold a median 12-month price target of $90 — +15.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$2.3B
Ticker Nerd rank
47 / 100
Median analyst target
$90
Analysts covering
9
Total return, dividends reinvested
1W
+1.3%
1M
+25.1%
YTD
−40.0%
1Y
−36.5%
From 52W high
−53.4%
From 52W low
+126.3%
$35
$168
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WGS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GeneDx Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
78
Accruals
73
Revisions
68
Value
54
Growth
41
Volatility
38
Momentum
38
Size
35
Issuance
17

Quality (78): The business earns solid, repeatable profits on what it owns.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WGS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WGS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Oct 25Jan 26Apr 26Jul 26WGSHigh $103Median $90Low $74

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $74Median $90High $103

The green dot is the last close — the median target sits +15.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Aug 2026BTIGReiteratesBuy$90
4 Aug 2026Canaccord GenuityMaintainsBuy$75 → $90
29 June 2026GuggenheimMaintainsBuy$70 → $74
29 June 2026GuggenheimMaintainsBuy—
23 June 2026Piper SandlerMaintainsOverweight—
23 June 2026Piper SandlerMaintainsOverweight$50 → $63
5 May 2026BTIGMaintainsBuy—
5 May 2026Canaccord GenuityMaintainsBuy—
5 May 2026GuggenheimMaintainsBuy—
5 May 2026Wells FargoMaintainsOverweight—
20 Apr 2026Canaccord GenuityMaintainsBuy—
30 Mar 2026GuggenheimMaintainsBuy—
24 Feb 2026BTIGMaintainsBuy—
24 Feb 2026Piper SandlerMaintainsOverweight—
9 Feb 2026Wells FargoUpgradeOverweight—
22 Dec 2025Canaccord GenuityMaintainsBuy—
15 Dec 2025Wells FargoMaintainsEqual-Weight—
12 Dec 2025BTIGMaintainsBuy—
4 Nov 2025Wells FargoMaintainsEqual-Weight—
29 Oct 2025BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WGS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

WGS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−102.5%
Analysts raising
0
Analysts cutting
1
Fundamentals

GeneDx Holdings Corp. (WGS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
724.6×

Cheaper than 1% of US stocks

Price / sales
5.1×

Cheaper than 25% of US stocks

Price / book
9.1×

Cheaper than 12% of US stocks

EV / EBITDA
−70.1×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
11.4%

Higher than 56% of US stocks

Earnings growth (YoY)
11.4%

Higher than 50% of US stocks

Gross margin
68.4%

Higher than 81% of US stocks

Operating margin
−15.2%

Higher than 23% of US stocks

Net margin
−23.4%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−40.8%

Higher than 24% of US stocks

Return on assets
−7.9%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

WGS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
WGSGeneDx Holdings Corp.$2.3B
47
CDNACareDx, Inc.$2.3B
100
NEONeoGenomics, Inc.$2.0B
76
GRALGRAIL, Inc.$3.0B
36
VCYTVeracyte, Inc.$3.3B
97
PSNLPersonalis, Inc.$1.5B
43
ADPTAdaptive Biotechnologies Corp.$4.0B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GeneDx Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WGS news & analysis

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy

Business Wire · 11 Aug 2026positive

GeneDx launched a new online offering to broaden access to exome testing for children with global developmental delay, intellectual disability, and epilepsy, aiming to help families receive answers more quickly.

Why it matters — This launch expands GeneDx's addressable market for exome testing and could accelerate adoption of the company's diagnostic services among families seeking genetic answers.

GeneDx to Participate in Upcoming Investor Conferences

Business Wire · 6 Aug 2026neutral

GeneDx announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences, according to a Business Wire release. No further details about the events were provided in the announcement.

Why it matters — Investor conference participation gives GeneDx management a platform to present the company to potential investors, which WGS watchers may follow for visibility and engagement.

Alger Small Cap Focus Fund Q2 2026 Portfolio Review

Seeking Alpha · 6 Aug 2026negative

The Alger Small Cap Focus Fund published its Q2 2026 portfolio review, in which GeneDx Holdings Corp. was listed among the top detractors from the fund's performance during the quarter. The review also highlighted Nebius Group, Credo Technology Group, and Guardant Health as top contributors.

Why it matters — For a GeneDx watcher, the fund's classification of GeneDx as a top detractor indicates the stock underperformed within this portfolio during Q2 2026.

GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

GeneDx Holdings Corp. published the transcript of its Q2 2026 earnings call via Seeking Alpha, presenting management's discussion of the company's second-quarter results and the accompanying Q&A session.

Why it matters — A WGS watcher would care because the transcript offers a direct record of management's own commentary on the company's latest quarterly performance.

GeneDx Q2 Earnings Call Highlights

MarketBeat · 3 Aug 2026positive

GeneDx reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company returned to adjusted profitability one quarter earlier than previously expected while maintaining its full-year 2026 outlook.

Why it matters — A WGS watcher would care because the company beat its revenue guidance, set a record testing volume, and achieved adjusted profitability ahead of schedule.

FAQ

Frequently asked questions about WGS stock

What is the WGS stock price forecast for 2026-2027?

The 9 Wall Street analysts covering GeneDx Holdings Corp. have a median 12-month price target of $90, with estimates ranging from $74 to $103. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WGS stock a buy right now?

Of the 9 analysts covering GeneDx Holdings Corp., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GeneDx Holdings Corp. 47 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WGS?

As at 15 Aug 2026, GeneDx Holdings Corp. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (78 of 100).

Will WGS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +15.3% from the last close, and Ticker Nerd's factor model ranks GeneDx Holdings Corp. 47 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WGS stock forecast for 2030?

No analyst covering GeneDx Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WGS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $103 over the next 12 months.

How has WGS stock performed over the past year?

GeneDx Holdings Corp. returned -36.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GeneDx Holdings Corp. do?

GeneDx Holdings Corp. is a leading genomics company specializing in genetic testing services for the diagnosis of rare and complex genetic disorders.

What is the latest news on WGS?

The most recent item we track (Business Wire, 11 Aug 2026): "GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy". GeneDx launched a new online offering to broaden access to exome testing for children with global developmental delay, intellectual disability, and epilepsy, aiming to help families receive answers more quickly.

Company

About GeneDx Holdings Corp.

GeneDx Holdings Corp. is a leading genomics company specializing in genetic testing services for the diagnosis of rare and complex genetic disorders. It provides advanced whole exome and genome sequencing, along with targeted gene panels and microarray testing, to deliver rapid, precise, and actionable clinical insights that inform personalized treatment plans and improve patient outcomes. The company leverages one of the largest rare disease datasets, powered by millions of tests, exomes, genomes, and phenotypic data points, enhanced by AI tools and expert interpretation to achieve higher diagnostic yields than traditional methods. GeneDx supports healthcare providers in addressing conditions such as autism spectrum disorders, developmental delays, epilepsy, cardiomyopathy, and various inherited diseases across pediatric and adult populations. Its offerings facilitate precision medicine by accelerating diagnoses, reducing diagnostic odysseys, and aiding drug discovery through comprehensive genomic analysis. Headquartered in Stamford, Connecticut, GeneDx Holdings Corp. serves clinicians, patients, and health systems seeking to integrate cutting-edge genomics into routine care.

CEO Ms. Katherine A. Stueland · 1,300 employees · United States · https://www.genedx.com